up on volume, page-2

This article shows several analysts ratings on Heartware. What l find intereseting is their ratings are neutral while FDA approval is pending. Watch these change when approval comes.

Definately good to see volumes rising.

Another interesting point is that CE approval was given 3 years ago now and the yanks are still farting about.

HeartWare (HTWR) Posts Large Volume Increase, 152,000 Shares Trade Hands.
Source: ABMN Staff | Publish date: Fri, 6 Jan 15:22 | >> Read article in News website

Back

HTWR
151,874 shares of HeartWare (HTWR) traded hands on Friday, a 136.35% increase in volume compared to its 20-day average. The stock last traded at $72.98, up from its previous close of $70.00.

Separately, analysts at Auriga reiterated a “hold” rating on shares of HeartWare in a research note to investors on Monday, October 31st. They now have a $73.00 price target on the stock. Analysts at Piper Jaffray (NYSE: PJC) reiterated a “neutral” rating on shares of HeartWare in a research note to investors on Monday, October 31st. Also, analysts at Wunderlich reiterated a “hold” rating on shares of HeartWare in a research note to investors on Friday, October 14th.

HeartWare International, Inc. (HeartWare) is a medical device company. The Company is engaged in the design, manufacture and marketing of medical devices for the treatment of advanced heart failure. Its product, the HeartWare Ventricular Assist System (the HeartWare System), which includes a left ventricular assist device (LVAD), or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients with advanced heart failure. The core of the HeartWare System is a continuous flow blood pump, the HVAD Pump, which is a full-output device capable of pumping up to 10 liters of blood per minute. In January 2009, the HeartWare System received Communaute Europeenne (CE) Marking approval, which allows it to market and sell the device in Europe.

HeartWare has a 52 week low of $53.40 and a 52 week high of $99.10. The stock’s 50-day moving average is $66.73 and its 200-day moving average is $65.38. The company has a market cap of $1.041 billion.